- Evinco Therapeutics is an Australian start-up on a mission to transform the treatment of Alzheimer’s disease and other neuroinflammatory conditions
Melbourne, Australia, 4 December 2025 – An exciting chapter in medical innovation begins today with the official launch of Evinco Therapeutics Pty Ltd (“Evinco” or “Company”), a Melbourne-based biotechnology company developing advanced immune-based therapies for neurological disorders under the leadership of CEO and Executive Chair, Prof. Alan Trounson AO.
Evinco is a spin-out from Cartherics Pty Ltd (“Cartherics”), allowing Cartherics to focus on its development programs in cancer and endometriosis. Evinco is raising capital to enable proof of concept studies.
The Company will conduct research into the use of Extracellular Vesicles (EVs) of Natural Killer (NK) cells as a novel treatment approach for Alzheimer’s Disease and other neurological conditions. These NK-EVs are being designed for intranasal delivery, providing a novel and simple method for transporting therapeutics directly into the affected area of the brain.
Alzheimer’s disease is the most common cause of dementia which is now the leading cause of death in Australia. The Alzheimer's disease therapeutics market is forecast to reach USD $17 billion by 2033 across the eight major markets driven by the ageing global population.
Evinco Therapeutics, CEO and Executive Chair, Prof. Alan Trounson AO, commented: “Serendipity has opened the incredible potential benefit of autologous NK cell therapy for Alzheimer’s disease. We have shown that minuscule EVs extracted from NK cells have extraordinary effects on microglia - the immune cells of the brain - in removing aggregated amyloid protein. I am excited that this and other neuroprotective properties of NK-EVs may herald a new frontier in the fight against Alzheimer’s disease and other neuroinflammatory diseases.”
With a brilliant scientific team, experienced managers, advisors and collaborators from leading academic institutions, medical centres and other company support, Evinco Therapeutics is on a mission to deliver a potential new and simple treatment opportunity for millions affected by neurological disorders worldwide. The company aims to accelerate the translation of research breakthroughs into real-world therapies, working to address the urgent need for effective interventions in response to rising dementia rates.
By leveraging the latest advances in immune cell therapy, Evinco Therapeutics aims to set new benchmarks for innovation and patient outcomes in the rapidly evolving field of neurodegenerative disease treatment.
About us:
About Evinco Therapeutics:
Evinco Therapeutics Pty Ltd is a privately held biotechnology company, based in Melbourne, Australia, developing innovative immune-based therapies for neurological disorders. The Company is focused on advancing NK cell-derived extracellular vesicles (EVs) for the treatment of Alzheimer’s disease. By pursuing innovative intranasal delivery methods for its NK-EV technology, Evinco aims to offer a safer and more accessible treatment that has the potential to significantly improve the lives of those affected by Alzheimer’s disease and related disorders. Evinco Therapeutics is a subsidiary of Cartherics Pty Ltd.
Contact details:
Christine Filippis
Teraze Communications
Phone: +61 419 119 866
Email: [email protected]
